4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit

Rhea-AI Summary

4D pharma plc (NASDAQ: LBPS) announced that CEO Duncan Peyton and CSO Alex Stevenson will participate in a fireside chat at the Chardan Metagenomics and Microbiome Medicines Summit on March 1, 2022, at 9:00 a.m. ET. The chat will be available for live streaming on the company's website, with replays accessible for 90 days.

4D pharma is a pioneer in developing Live Biotherapeutics—drugs derived from the microbiome. The company has five clinical programs including studies on MRx0518 and Blautix® focusing on various cancers and irritable bowel syndrome.

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Officer of 4D pharma, will participate in a fireside chat at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 9:00 a.m. ET (2:00 p.m. GMT).

A webcast of the fireside chat will be available via the ‘Events’ section of the 4D pharma website at www.4dpharmaplc.com and will be available to replay for 90 days following the presentation.

About 4D pharma
4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D pharma has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in irritable bowel syndrome (IBS) which has completed a successful Phase II trial. A Phase I study of MRx0005 and MRx0029 in patients with Parkinson’s disease is expected to commence in 2022. Additional preclinical-stage programs include candidates for CNS disease, immune-inflammatory conditions and cancer. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220223005215/en/

4D pharma

Investor Relations ir@4dpharmaplc.com

Singer Capital Markets – Nominated Adviser and Joint Broker

Philip Davies / James Fischer (Corporate Finance) +44 (0)20 7496 3000

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker

Dominic Wilson +44 (0)20 7332 2500

Stern Investor Relations

Julie Seidel +1-212-362-1200

Julie.seidel@sternir.com

Image Box Communications

Neil Hunter / Michelle Boxall +44 (0)20 8943 4685

neil@ibcomms.agency / michelle@ibcomms.agency

6 Degrees

Lynne Dardanell +1-336-202-9689

ldardanell@6degreespr.com

Source: 4D pharma

FAQ

What is the date and time of 4D pharma's presentation at the Chardan Summit?

4D pharma's presentation at the Chardan Metagenomics and Microbiome Medicines Summit is scheduled for March 1, 2022, at 9:00 a.m. ET.

Who will be speaking at the Chardan Summit for 4D pharma?

Duncan Peyton, the CEO, and Alex Stevenson, the CSO, will represent 4D pharma at the Chardan Summit.

Where can I watch the 4D pharma fireside chat?

The fireside chat can be streamed live on 4D pharma's official website in the 'Events' section.

What is the focus of 4D pharma's clinical programs?

4D pharma's clinical programs focus on Live Biotherapeutics for conditions like cancer and irritable bowel syndrome.

How long will the webcast of the 4D pharma presentation be available?

The webcast will be available for replay for 90 days following the presentation.